Your browser doesn't support javascript.
loading
Identification of BCL-XL as highly active survival factor and promising therapeutic target in colorectal cancer.
Scherr, Anna-Lena; Mock, Andreas; Gdynia, Georg; Schmitt, Nathalie; Heilig, Christoph E; Korell, Felix; Rhadakrishnan, Praveen; Hoffmeister, Paula; Metzeler, Klaus H; Schulze-Osthoff, Klaus; Illert, Anna L; Boerries, Melanie; Trojan, Jörg; Waidmann, Oliver; Falkenhorst, Johanna; Siveke, Jens; Jost, Philipp J; Bitzer, Michael; Malek, Nisar P; Vecchione, Loredana; Jelas, Ivan; Brors, Benedikt; Glimm, Hanno; Stenzinger, Albrecht; Grekova, Svetlana P; Gehrig, Tobias; Schulze-Bergkamen, Henning; Jäger, Dirk; Schirmacher, Peter; Heikenwalder, Mathias; Goeppert, Benjamin; Schneider, Martin; Fröhling, Stefan; Köhler, Bruno C.
Afiliação
  • Scherr AL; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120, Heidelberg, Germany.
  • Mock A; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120, Heidelberg, Germany.
  • Gdynia G; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
  • Schmitt N; German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
  • Heilig CE; Institute of Pathology, University Hospital Heidelberg, 69120, Heidelberg, Germany.
  • Korell F; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120, Heidelberg, Germany.
  • Rhadakrishnan P; Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
  • Hoffmeister P; German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
  • Metzeler KH; Department of Medicine V, University Hospital Heidelberg, 69120, Heidelberg, Germany.
  • Schulze-Osthoff K; Department of General, Visceral and Transplantation Surgery, University of Heidelberg, 69120, Heidelberg, Germany.
  • Illert AL; Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, 69120, Heidelberg, Germany.
  • Boerries M; Department of Medicine III, University Hospital, LMU Munich, 81377, Munich, Germany.
  • Trojan J; German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
  • Waidmann O; Department of Molecular Medicine, Interfaculty Institute for Biochemistry, University of Tübingen, 72076, Tübingen, Germany.
  • Falkenhorst J; Department of Internal Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.
  • Siveke J; German Cancer Consortium (DKTK) Partner Site Freiburg and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
  • Jost PJ; Comprehensive Cancer Center Freiburg (CCCF), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.
  • Bitzer M; German Cancer Consortium (DKTK) Partner Site Freiburg and German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
  • Malek NP; Comprehensive Cancer Center Freiburg (CCCF), Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.
  • Vecchione L; Institute of Medical Bioinformatics and Systems Medicine, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, 79106, Freiburg, Germany.
  • Jelas I; Department of Medicine 1, University Hospital Frankfurt, 60590, Frankfurt, Germany.
  • Brors B; Universitäres Centrum für Tumorerkrankungen (UCT), University Hospital Frankfurt, 60590, Frankfurt, Germany.
  • Glimm H; Department of Medicine 1, University Hospital Frankfurt, 60590, Frankfurt, Germany.
  • Stenzinger A; Universitäres Centrum für Tumorerkrankungen (UCT), University Hospital Frankfurt, 60590, Frankfurt, Germany.
  • Grekova SP; Department of Medical Oncology, Sarcoma Center, West German Cancer Center, University Duisburg-Essen, Medical School, 45147, Essen, Germany.
  • Gehrig T; DKTK partner site Essen and German Cancer Consortium (DKTK), 69120, Heidelberg, Germany.
  • Schulze-Bergkamen H; Institute for Developmental Cancer Therapeutics, West German Cancer Center, University Hospital Essen, 45147, Essen, Germany.
  • Jäger D; Division of Solid Tumor Translational Oncology, German Cancer Consortium (DKTK, partner site Essen) and German Cancer Research Center, DKFZ, 69120, Heidelberg, Germany.
  • Schirmacher P; Medical Department III for Hematology and Oncology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, 81675, Munich, Germany.
  • Heikenwalder M; Central Institute for Translational Cancer Research (Translatum), Technical University of Munich, 81675, Munich, Germany.
  • Goeppert B; German Consortium for Translational Cancer Research (DKTK) partner site TUM, German Cancer Research Center Heidelberg (DKFZ), 69120, Heidelberg, Germany.
  • Schneider M; Department of Internal Medicine I, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Fröhling S; Department of Internal Medicine I, University Hospital Tübingen, 72076, Tübingen, Germany.
  • Köhler BC; Charité Comprehensive Cancer Center, 10117, Berlin, Germany.
Cell Death Dis ; 11(10): 875, 2020 10 17.
Article em En | MEDLINE | ID: mdl-33070156
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteína bcl-X / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Cell Death Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Proteína bcl-X / Antineoplásicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Cell Death Dis Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Reino Unido